logo

Our mission is to ensure the generation of accurate and precise findings.

GET UPDATE

Please enter subscribe form shortcode

December 29, 2022 No Comments

Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen

The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”

Leave a Reply